StockData
Zoetis Inc. logo

Zoetis Inc. (ZTS) company profile

ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3046% below fair value
$83.48−0.91 (-1.08%)

Close on Nov 17, 2026Market cap $34.50BP/E 13.7Yield 2.43%

About Zoetis

Pharmaceutical Preparations, SIC 2834

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, diagnostic products, and precision animal health solutions. The enterprise organizes operations into United States and International segments, offering therapies across companion animals and livestock. Core categories include parasiticides, dermatology, vaccines, anti-infectives, and pain management products, alongside diagnostics and genetic tests. The company serves veterinarians, livestock producers, and pet owners through direct sales, veterinary distributors, retail pharmacies, and e-commerce channels.

Headquartered in Parsippany, New Jersey, the company markets products directly in approximately 45 countries and sells into more than 100 countries across North America, Europe, Africa, Asia, Australia, and South America. Its operational footprint features a dedicated research and development headquarters in Kalamazoo, Michigan, and a network of 21 company-operated manufacturing sites across multiple continents, supplemented by more than 90 contract manufacturing organizations. The enterprise maintains global operations supported by approximately 3,900 sales and technical personnel and 1,700 research and development staff.

Summary of the business section of Zoetis's latest annual report, written by StockData.

Company profile

Company

Legal name
Zoetis Inc.
Founded
2012
Headquarters
Parsippany, NJ
Address
10 Sylvan Way 07054
Phone
(973) 822-7000
Employees
14,500, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
KPMG LLP, Short Hills, NJ

Stock & identifiers

Ticker
ZTS
Exchange
NYSE
IPO date
Feb 4, 2013
Shares outstanding
413M, Jul 31, 2026
Public float
$69.23B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1555280
CUSIP
98978V103
ISIN
US98978V1035
FIGI
BBG0039320N9
Share class FIGI
BBG0039320P7
LEI
549300HD9Q1LOC9KLJ48
EIN
46-0696167

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kristin C. PeckChief Executive Officer, Director105,902
Kevin EschExecutive Vice President702
Keith SarbaughExecutive Vice President3,346
Abhay U. NayakExecutive Vice President0
Julie FullerExecutive Vice President1,588
Roxanne LaganoExecutive Vice President16,466
Astorga Jeannette FerranExecutive Vice President1,874
Rimma DriscollExecutive Vice President5,894
James SaccaroEVP, CFO & COO0
Wetteny JosephChief Financial Officer22,816
Jamie BrannanExecutive Vice President4,301
Nicholas AshtonExecutive Vice President2,214
Robert J. PolzerExecutive Vice President5,208
Mark StetterDirector1,572
Frank A. DamelioDirector21,458
Michael B. McCallisterDirector31,893
Louise M. ParentDirector18,208
Paul BisaroDirector27,862
Gregory NordenDirector18,167
Khosla SanjayDirector1,892
Gavin HattersleyDirector3,354
Vanessa BroadhurstDirector3,920
Willie M. ReedDirector12,864
Antoinette Renee LeatherberryDirector5,280
Stephanie TileniusDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$19.05M$2.77M$4.02M$80$188
FY2024$17.21M$759.62K$3.35M$102$148
FY2023$15.24M$26.37M$2.99M$122$137
FY2022$14.00M-$15.71M$2.93M$90$136
FY2021$13.10M$33.52M$4.46M$148$126
FY2020$10.37M$15.56M$3.76M$126$108

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Kristin C. Peck
Chief Executive Officer
$1.35M$10.22M$3.41M$2.19M$1.88M$19.05M+11%
Wetteny Joseph
Executive Vice President (“EVP”) and Chief Financial Officer
$800.00K$2.85M$949.96K$832.00K$164.94K$5.60M+10%
Jamie Brannan
EVP and Chief Commercial Officer
$720.00K$1.67M$557.99K$673.92K$348.53K$3.97M+31%
Robert J. Polzer
Former EVP and President of Research and Development
$710.00K$1.67M$555.46K$590.72K$144.72K$3.67M+23%
Roxanne Lagano
EVP, General Counsel and Corporate Secretary
$700.00K$1.04M$347.50K$604.80K$130.79K$2.83M+8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 4, 2013
Offer price
$26.00
Securities offered
86,100,000
Gross proceeds
$2.24B
Exchange
NYSE
First trading day
Feb 1, 2013
First-day close
$31.01+19.3%
Lock-up ends (est.)
Jul 31, 2013

“Our Class A common stock has been approved for listing on the New York Stock Exchange, or NYSE, under the symbol “ZTS.” The initial public offering price is $26.00 per share of Class A common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 14,500 employees worldwide, which included approximately 6,800 employees in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?